Literature DB >> 32314127

The Complexity of Targeting Chemokines to Promote a Tumor Immune Response.

Marianne Strazza1, Adam Mor2.   

Abstract

Immunotherapeutic treatment strategies greatly extend patient survival following malignant disease across a wide range of tumor types, including even those with metastatic disease. While diverse in approach, adoptive cell therapy, introduction of T cells that express chimeric antigen receptors, and checkpoint inhibitors all aim to re-invigorate the immune system to promote tumor cell identification and elimination. This review will focus on immune cell infiltration into tumors as well as a cellular organization within the tumor microenvironment as directed by the cell-specific expression patterns of chemokines and chemokine receptors. Through better understanding the chemokine network within tumors, we can uncover mechanisms to promote beneficial immune cell infiltration that can be combined with checkpoint inhibition. Conversely, chemokine expression is not limited to cells of the immune system, and it is understood that tumor cells also express chemokines and chemokine receptors. Tumor cells can hijack the chemokine networks to promote immune suppression and metastatic tumor cell trafficking. We will discuss the ways in which the chemokine network lies at the crossroad of immune evasion and tumor regression. Overall, this review will summarize key publications in the field of immune cell recruitment to tumors, highlight the dichotomous nature of chemokine interventions into cancer, and aims to identify therapeutic pathways forward.

Entities:  

Keywords:  T cells; chemokines; immune checkpoint; tumor infiltration

Mesh:

Substances:

Year:  2020        PMID: 32314127      PMCID: PMC8270394          DOI: 10.1007/s10753-020-01235-8

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.657


  49 in total

Review 1.  Cancer and the chemokine network.

Authors:  Fran Balkwill
Journal:  Nat Rev Cancer       Date:  2004-07       Impact factor: 60.716

Review 2.  T cell chemokine receptor patterns as pathogenic signatures in autoimmunity.

Authors:  Marianne Strazza; Inbar Azoulay-Alfaguter; Gregg J Silverman; Adam Mor
Journal:  Discov Med       Date:  2015-02       Impact factor: 2.970

Review 3.  Consider the chemokines: a review of the interplay between chemokines and T cell subset function.

Authors:  Marianne Strazza; Adam Mor
Journal:  Discov Med       Date:  2017-08       Impact factor: 2.970

4.  Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib.

Authors:  P A Ascierto; K D Lewis; A M Di Giacomo; L Demidov; M Mandalà; I Bondarenko; C Herbert; A Mackiewicz; P Rutkowski; A Guminski; B Simmons; C Ye; G Hooper; M J Wongchenko; G R Goodman; Y Yan; D Schadendorf
Journal:  Ann Oncol       Date:  2020-01       Impact factor: 32.976

5.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

6.  Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.

Authors:  Melvyn T Chow; Aleksandra J Ozga; Rachel L Servis; Dennie T Frederick; Jennifer A Lo; David E Fisher; Gordon J Freeman; Genevieve M Boland; Andrew D Luster
Journal:  Immunity       Date:  2019-05-13       Impact factor: 31.745

Review 7.  Chemokines in cancer.

Authors:  Melvyn T Chow; Andrew D Luster
Journal:  Cancer Immunol Res       Date:  2014-12       Impact factor: 11.151

8.  Structure and functional expression of a human interleukin-8 receptor.

Authors:  W E Holmes; J Lee; W J Kuang; G C Rice; W I Wood
Journal:  Science       Date:  1991-09-13       Impact factor: 47.728

9.  Cloning of complementary DNA encoding a functional human interleukin-8 receptor.

Authors:  P M Murphy; H L Tiffany
Journal:  Science       Date:  1991-09-13       Impact factor: 47.728

10.  Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Charissa A C Jessurun; Julien A M Vos; Jacqueline Limpens; Rosalie M Luiten
Journal:  Front Oncol       Date:  2017-09-27       Impact factor: 6.244

View more
  6 in total

1.  Oncogenic pathways activated by pro-inflammatory cytokines promote mutant p53 stability: clue for novel anticancer therapies.

Authors:  Gabriella D'Orazi; Marco Cordani; Mara Cirone
Journal:  Cell Mol Life Sci       Date:  2020-10-17       Impact factor: 9.261

Review 2.  The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?

Authors:  Shunchuan Zhang; Samuel D Rabkin
Journal:  Expert Opin Drug Discov       Date:  2020-12-14       Impact factor: 6.098

Review 3.  Cutting-Edge Platforms for Analysis of Immune Cells in the Hepatic Microenvironment-Focus on Tumor-Associated Macrophages in Hepatocellular Carcinoma.

Authors:  Daniel E Millian; Omar A Saldarriaga; Timothy Wanninger; Jared K Burks; Yousef N Rafati; Joseph Gosnell; Heather L Stevenson
Journal:  Cancers (Basel)       Date:  2022-04-07       Impact factor: 6.575

Review 4.  Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases and Cancer.

Authors:  Qianmiao Wu; Huaijun Tu; Jian Li
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

5.  A pan-cancer analysis of the expression of gasdermin genes in tumors and their relationship with the immune microenvironment.

Authors:  Yuan-Yuan Wang; Lin-Yang Shi; Ming-Hao Xu; Yu Jing; Cui-Cui Sun; Jia-Hui Yang; Ruo-Nan Wang; Ning-Ning Sheng; Ca-Fa Zhang; Li Zhang; Zhi-Tu Zhu; Qing-Jun Wang
Journal:  Transl Cancer Res       Date:  2021-09       Impact factor: 1.241

6.  Development of an immune-related prognostic index associated with osteosarcoma.

Authors:  Chao-Dong Yin; Ying-Lan Hou; Xiao-Ren Liu; Yu-Sheng He; Xin-Ping Wang; Cheng-Jie Li; Xiao-Hong Tan; Jun Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.